GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » EV-to-EBIT
中文

DexCom (DexCom) EV-to-EBIT

: 72.32 (As of Today)
View and export this data going back to 2005. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, DexCom's Enterprise Value is $52,846 Mil. DexCom's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $731 Mil. Therefore, DexCom's EV-to-EBIT for today is 72.32.

The historical rank and industry rank for DexCom's EV-to-EBIT or its related term are showing as below:

DXCM' s EV-to-EBIT Range Over the Past 10 Years
Min: -559.89   Med: -66.74   Max: 414.55
Current: 72.32

During the past 13 years, the highest EV-to-EBIT of DexCom was 414.55. The lowest was -559.89. And the median was -66.74.

DXCM's EV-to-EBIT is ranked worse than
89.68% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 19.86 vs DXCM: 72.32

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. DexCom's Enterprise Value for the quarter that ended in Dec. 2023 was $47,694 Mil. DexCom's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $731 Mil. DexCom's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 1.53%.


DexCom EV-to-EBIT Historical Data

The historical data trend for DexCom's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 119.53 111.92 186.91 106.09 65.27

DexCom Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 106.09 101.89 94.37 57.54 65.27

Competitive Comparison

For the Medical Devices subindustry, DexCom's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexCom EV-to-EBIT Distribution

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where DexCom's EV-to-EBIT falls into.



DexCom EV-to-EBIT Calculation

DexCom's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=52846.001/730.7
=72.32

DexCom's current Enterprise Value is $52,846 Mil.
DexCom's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $731 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DexCom  (NAS:DXCM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

DexCom's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=730.7/47694.186
=1.53 %

DexCom's Enterprise Value for the quarter that ended in Dec. 2023 was $47,694 Mil.
DexCom's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $731 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DexCom EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of DexCom's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


DexCom (DexCom) Business Description

Address
6340 Sequence Drive, San Diego, CA, USA, 92121
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Executives
Sadie Stern officer: Chief Human Resources Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman director
Kevin R Sayer director
Jereme M Sylvain officer: SVP, Finance & CAO 6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Jacob Steven Leach officer: SVP, Research & Development 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Nicholas Augustinos director 754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Micheal Jon Brown officer: EVP, Chief Legal Officer 6340 SEQUENCE DR, SAN DIEGO CA 92121
Steven Robert Pacelli officer: Vice President Legal Affairs 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan officer: EVP Chief Technology Officer C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan officer: EVP Operations 1023 CHERRY ROAD, MEMPHIS TN 38117
Bridgette P Heller director TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Matthew Vincent Dolan officer: * 6340 SEQUENCE DR, SAN DIEGO CA 92121
Rimma Driscoll director C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Shelly Ramasamy Selvaraj officer: SVP Information Technology 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Paul R Flynn officer: EVP, Global Revenue 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121

DexCom (DexCom) Headlines

From GuruFocus

Q2 2022 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Dexcom Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Dexcom Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Dexcom Inc at Wells Fargo Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024